Ulcers

Ulcers / 2011 / Article / Tab 1

Clinical Study

Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

Table 1

Summary of clinical parameters before and after administration of Lactobacillus Brevis CD2 or placebo lozenges.

Lactobacillus brevis CD2 ( 𝑛 = 1 5 )Placebo ( 𝑛 = 1 5 )Intergroup comparison

Severe ( 𝑛 )Moderate ( 𝑛 )Mild ( 𝑛 )Absent ( 𝑛 )Total ValueSevere ( 𝑛 )Moderate ( 𝑛 )Mild ( 𝑛 )Absent ( 𝑛 )Total value

Burningbefore753034843035 𝑃 = . 9
after001141242716 𝑃 = . 0 3

Spontaneous painbefore663033753034 𝑃 = n a
after00101341718 𝑃 = . 0 2

Caused painbefore9600391050040 𝑃 = n a
after001141521720 𝑃 = . 0 2

Perilesional erythemabefore672034753034 𝑃 = N A
after00101341718 𝑃 = . 0 2

Value assignment: 0: absent, 1: mild, 2: moderate, and 3: severe.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.